Thrombophilia genetic testing in Romanian young women with acute thrombotic events: role of Factor V Leiden, Prothrombin G20210A, MTHFR C677T and A1298C polymorphisms / Evaluarea genetică a trombofiliilor la femei tinere din România cu evenimente acute trombotice: rolul Factorului V Leiden, Protrombinei G20210A, polimorfismelor MTHFR C677T și A1298C

Open access

Abstract

Objective: The present case-control study aimed at evaluating the contribution of thrombophilic polymorphisms to acute venous (VTE) as well as arterial thrombotic events (ATE) in a population of young women with few traditional thrombotic factors (CVRF).

Methods: We consecutively enrolled patients under 45 years of age, with less than 3 CVRF, evaluated for VTE or ATE, women and men as a comparator. The control group consisted of healthy young women. A thrombophilia panel and genetic testing for Factor V Leiden (FVL), G20210A Prothrombin and MTHFR polimorphisms were done.

Results: A total of 323 persons were enrolled: 71 women and 121 men with thromboembolic events, and 131 healthy female as controls. Hyperhomocysteinemia was more frequent in ATE (30.4%) than VTE female patients (6.25%), p<0.01. Genetic testing was available in 45 women and 84 men with acute thrombotic events and in all controls. Homozygous FVL was associated with VTE in young women (10.3% vs 0% controls, p<0.01). Prothrombin G20210A polymorphism had the lowest prevalence – 5.4% and only heterozygosity was found. MTHFR C677T heterozygosity showed no significant difference between women patients and controls (62.2 % vs 43.5% respectively, p=0.1). The homozygous status, less frequent (6.6%), was not associated with ATE or VTE. Homozygous MTHFR A1298C was associated with VTE in women (17.2% patients vs 4.5% controls, OR 4.34, p 0.02, CI 1.22-15.3).

Conclusion: In young women with few CVRF, mild hyperhomocysteinemia, homozygosity for FVL and for MTHFR A1298C polymorphisms increase the risk for VTE but not ATE. MTHFR polymorphisms are found with increased frequency in both healthy persons and patients therefore, their significance as an important thrombotic risk modifier remains unclear.

1. Spencer FA, Kroll A, Lessard D, Emery C, Glushchenko AV, Pacifico L, et al. Isolated calf deep vein thrombosis in the community setting: the Worcester Venous Thromboembolism study. J. Thromb. Thrombolysis. 2012;33(3):211-7. DOI: 10.1007/s11239-011-0670-x.

2. Ng KW, Loh PK, Sharma VK. Role of investigating thrombophilic disorders in young stroke. Stroke research and treatment. 2011;2011.

3. Yokus O, Albayrak M, Balcik OS, Ceran F, Dagdas S, Yilmaz M, et al. Risk factors for thrombophilia in young adults presenting with thrombosis. Int. J. Hematol. 2009;90(5):583-90. DOI: 10.1007/s12185-009-0447-6.

4. Jadaon MM. Epidemiology of activated protein C resistance and Factor V Leiden mutation in the Mediterranean Region. Mediterr. J. Hematol. Infect. Dis. 2011;3:e2011037. DOI: 10.4084/mjhid.2011.037 DOI: 10.4084/mjhid.2011.054.

5. Jadaon MM. Epidemiology of Prothrombin G20210A Mutation in the Mediterranean Region. Mediterr.

J. Hematol. Infect. Dis. 2011;3(1):e2011054. DOI: 10.4084/mjhid.2011.037 DOI: 10.4084/mjhid.2011.054.

6. Prandoni P. Links between arterial and venous disease. J. Intern. Med. 2007;262(3):341-50. DOI: 10.1111/j.1365-2796.2007.01815.x.

7. Prandoni P. Venous and arterial thrombosis: Two aspects of the same disease? Clin. Epidemiol. 2009;1:1. DOI: 10.1016/j.ejim.2009.02.001 DOI: 10.2147/clep. s4780.

8. Collaboration HS. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288(16):2015-22. DOI: 10.1001/ jama.288.16.2015.

9. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch. Pathol. Lab. Med. 2007;131(6):872-84.

10. Trenor CC, Chung RJ, Michelson AD, Neufeld EJ, Gordon CM, Laufer MR, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347-57. DOI: 10.1542/ peds.2010-2221.

11. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for testing for heritable thrombophilia. Br. J. Haematol. 2010;149(2):209-20. DOI: 10.1111/j.1365-2141.2009.08022.x.

12. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Greaves M, et al. Screening for thrombophilia in highrisk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. 2006.

13. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64-7. DOI: 10.1038/369064a0.

14. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler. Thromb. Vasc. Biol. 1997;17(11):2418-22. DOI: 10.1161/01.ATV.17.11.2418.

15. A ZC, Yang Y, Zhang SZ, Li N, Zhang W. Single nucleotide polymorphism C677T in the methylenetetrahydrofolate reductase gene might be a genetic risk factor for infertility for Chinese men with azoospermia or severe oligozoospermia. Asian J Androl. 2007;9(1):57-62. DOI: 10.1111/j.1745-7262.2007.00225.x.

16. Wu J, Li Y-z, Ma H-y, Bai J, Chen F, Fu S-b. Association between single nucleotide polymorphisms of MTHFR gene and susceptibility of psoriasis. Int J Genet. 2007;30(3):173-7.

17. Shaheen K, Alraies MC, Alraiyes AH, Christie R. Factor V Leiden: How great is the risk of venous thromboembolism? Cleve. Clin. J. Med. 2012;79(4):265-72. DOI: 10.3949/ccjm.79a.11072.

18. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular Disease in Women A Statement for Healthcare Professionals From the American Heart Association.Circulation. 1997;96(7):2468-82. DOI: 10.1161/01. CIR.96.7.2468

10. Trenor CC, Chung RJ, Michelson AD, Neufeld EJ, Gordon CM, Laufer MR, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347-57. DOI: 10.1542/ peds.2010-2221.

11. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for testing for heritable thrombophilia. Br. J. Haematol. 2010;149(2):209-20. DOI: 10.1111/j.1365-2141.2009.08022.x.

12. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Greaves M, et al. Screening for thrombophilia in highrisk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. 2006.

13. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64-7. DOI: 10.1038/369064a0.

14. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler.Thromb. Vasc. Biol. 1997;17(11):2418-22. DOI: 10.1161/01.ATV.17.11.2418.

15. A ZC, Yang Y, Zhang SZ, Li N, Zhang W. Single nucleotide polymorphism C677T in the methylenetetrahydrofolate reductase gene might be a genetic risk factor for infertility for Chinese men with azoospermia or severe oligozoospermia. Asian J Androl. 2007;9(1):57-62. DOI: 10.1111/j.1745-7262.2007.00225.x.

16. Wu J, Li Y-z, Ma H-y, Bai J, Chen F, Fu S-b. Association between single nucleotide polymorphisms of MTHFR gene and susceptibility of psoriasis. Int J Genet. 2007;30(3):173-7.

17. Shaheen K, Alraies MC, Alraiyes AH, Christie R. Factor V Leiden: How great is the risk of venous thromboembolism? Cleve. Clin. J. Med. 2012;79(4):265-72.DOI: 10.3949/ccjm.79a.11072.

18. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular Disease in Women A Statement for Healthcare Professionals From the American Heart Association. Circulation. 1997;96(7):2468-82. DOI: 10.1161/01. CIR.96.7.2468.

19. Lowe G. Common risk factors for both arterial and venous thrombosis. Br. J. Haematol. 2008;140(5):488-95. DOI: 10.1111/j.1365-2141.2007.06973.x.

20. Zoller B, de Frutos PG, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica. 1999;84(1):59-70.

21. Chan MY, Andreotti F, Becker RC. Hypercoagulable states in cardiovascular disease. Circulation. 2008;118(22):2286-97. DOI: 10.1161/CIRCULATIONAHA.108.778837.

22. Otten AM, Maas AH, Ottervanger JP, Kloosterman A, van’t Hof AW, Dambrink JHE, et al. Is the difference in outcome between men and women treated by primary percutaneous coronary intervention age dependent? Gender difference in STEMI stratified on age. European Heart Journal: Acute Cardiovascular Care. 2013;2(4):334-41. DOI: 10.1177/2048872612475270.

23. Yang X-P, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr. Opin. Nephrol. Hypertens. 2011;20(2):133. DOI: 10.1097/ MNH.0b013e3283431921.

24. Maas A, Appelman Y. Gender differences in coronary heart disease. Neth. Heart J. 2010;18(12):598-603. DOI: 10.1007/s12471-010-0841-y.

25. Hanson NQ, Aras O, Yang F, Tsai MY. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin. Chem. 2001;47(4):661-6.

26. de Bree A, Verschuren WM, Bjorke-Monsen AL, van der Put NM, Heil SG, Trijbels FJ, et al. Effect of the methylenetetrahydrofolate reductase 677C-- >T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am. J. Clin. Nutr. 2003;77(3):687-93.

27. Rosendorff A, Dorfman DM. Activated protein C resistance and factor V Leiden. Arch. Pathol. Lab. Med. 2007;131(6):866-71.

28. Djordjevic V, Rakicevic L, Mikovic D, Kovac M, Miljic P, Radojkovic D, et al. Prevalence of factor V leiden, factor V cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations. Acta Haematol. 2004;112(4):227-9. DOI: 10.1159/000081280.

29. Jukić I, Bingulac-Popović J, Đogić V, Babić I, Culej J, Tomičić M, et al. ABO blood groups and genetic risk factors for thrombosis in Croatian population. Croat. Med. J. 2009;50(6):550-8. DOI: 10.3325/ cmj.2009.50.550.

30. Stankovics J, Melegh B, Nagy A, Kis A, Molnar J, Losonczy H, et al. [Incidence of factor V G1681A (Leiden) mutation in samplings from the Hungarian population]. Orv. Hetil. 1998;139(19):1161-3.

31. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb. Haemost. 1998;79(5):912-5.

32. Rosendaal F, Siscovick D, Schwartz S, Beverly R, Psaty B, Longstreth Jr W, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89(8):2817-21.

33. Hotoleanu C, Popp R, Trifa A. Factor V Leiden, prothrombin G20210A and MTHFR C677T mutations in Romanian patients with deep venous thrombosis. HVM Bioflux. 2014;6(1):15-9.

34. Alfirevic Z, Simundic A-M, Nikolac N, Sobocan N, Alfirevic I, Stefanovic M, et al. Frequency of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case-control study. Biochemia Medica. 2010;20(2):229-35. DOI: 10.11613/ BM.2010.028.

35. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999;99(8):999-1004. DOI: 10.1161/01.CIR.99.8.999

36. Hotoleanu C, Trifa A, Popp R, Fodor D. The Importance of homozygous polymorphisms of methylenetetrahydrofolate reductase gene in romanian patients with idiopathic venous thromboembolism. Balkan medical journal. 2013;30(2):197. DOI: 10.5152/balkanmedj. 2013.7159.

37. Shmeleva VM, Kapustin SI, Papayan LP, Sobczyńska- Malefora A, Harrington DJ, Savidge GF. Prevalence of hyperhomocysteinemia and the MTHFR C677T polymorphism in patients with arterial and venous thrombosis from North Western Russia. Thromb. Res. 2003;111(6):351-6. DOI: 10.1016/j.thromres. 2003.10.004.

38. Nizankowska-Mogilnicka E, Adamek L, Grzanka P, Domagala T, Sanak M, Krzanowski M, et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur. Respir. J. 2003;21(1):25-30. DOI: 10.1183/09031936.03.00034302.

39. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C→ T polymorphism and venous thrombosis: results from the MEGA study. Arch. Intern. Med. 2007;167(5):497-501.DOI: 10.1001/archinte.167.5.497.

40. De Stefano V, Zappacosta B, Persichilli S, Rossi E, Casorelli I, Paciaroni K, et al. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br. J. Haematol. 1999;106(2):564-8. DOI: 10.1046/j.1365-2141.1999.01613.x.

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 281 243 19
PDF Downloads 105 98 5